Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
20.69
USD
|
+0.88%
|
|
+2.83%
|
+243.12%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
82.31
|
56.12
|
143.9
|
797.4
|
-
|
-
|
Enterprise Value (EV)
1 |
-24.41
|
-11.47
|
143.9
|
530.4
|
477.4
|
449.4
|
P/E ratio
|
-2.53
x
|
-1.27
x
|
-2.52
x
|
-11
x
|
-8.98
x
|
-7.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
372
x
|
-
|
165
x
|
EV / Revenue
|
-
|
-
|
-
|
248
x
|
-
|
93
x
|
EV / EBITDA
|
0.88
x
|
0.26
x
|
-2.53
x
|
-7.64
x
|
-5.79
x
|
-4.54
x
|
EV / FCF
|
-
|
0.3
x
|
-
|
-9.23
x
|
-5.22
x
|
-4.59
x
|
FCF Yield
|
-
|
332%
|
-
|
-10.8%
|
-19.1%
|
-21.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,867
|
17,215
|
23,857
|
38,880
|
-
|
-
|
Reference price
2 |
4.880
|
3.260
|
6.030
|
20.51
|
20.51
|
20.51
|
Announcement Date
|
3/3/22
|
3/2/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
2.143
|
-
|
4.834
|
EBITDA
1 |
-
|
-27.84
|
-44.79
|
-56.75
|
-69.47
|
-82.42
|
-99.05
|
EBIT
1 |
-
|
-27.84
|
-44.8
|
-56.76
|
-75.24
|
-101
|
-124.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-3,511.33%
|
-
|
-2,577.42%
|
Earnings before Tax (EBT)
1 |
-
|
-27.8
|
-43.94
|
-54.42
|
-66.07
|
-93.53
|
-113.9
|
Net income
1 |
-14.4
|
-27.8
|
-43.94
|
-54.42
|
-66.07
|
-93.53
|
-120
|
Net margin
|
-
|
-
|
-
|
-
|
-3,083.31%
|
-
|
-2,481.4%
|
EPS
2 |
-5.220
|
-1.930
|
-2.560
|
-2.390
|
-1.863
|
-2.284
|
-2.646
|
Free Cash Flow
1 |
-
|
-
|
-38.06
|
-
|
-57.45
|
-91.4
|
-97.95
|
FCF margin
|
-
|
-
|
-
|
-
|
-2,681%
|
-
|
-2,026.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/19/21
|
3/3/22
|
3/2/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.143
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-9.619
|
-11.56
|
-11.88
|
-11.73
|
-11.96
|
-15.64
|
-13.58
|
-15.57
|
-18.11
|
-16.61
|
-17.17
|
-17.58
|
-19.87
|
-
|
EBIT
1 |
-8.794
|
-9.62
|
-11.57
|
-11.88
|
-11.73
|
-11.96
|
-15.64
|
-13.58
|
-15.57
|
-18.11
|
-18.12
|
-19.35
|
-20.57
|
-19.87
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-903.08%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.773
|
-9.597
|
-11.41
|
-11.6
|
-11.34
|
-11.46
|
-15
|
-12.93
|
-15.03
|
-14.99
|
-15.86
|
-17.16
|
-18.45
|
-15
|
-
|
Net income
1 |
-8.773
|
-9.597
|
-11.41
|
-11.6
|
-11.34
|
-11.46
|
-15
|
-12.93
|
-15.03
|
-14.99
|
-15.86
|
-17.16
|
-18.45
|
-15
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-800.97%
|
-
|
-
|
-
|
EPS
2 |
-0.5200
|
-0.5600
|
-0.6700
|
-0.6800
|
-0.6600
|
-0.5600
|
-0.6500
|
-0.5500
|
-0.6200
|
-0.4200
|
-0.4377
|
-0.4182
|
-0.5086
|
-0.5353
|
-0.6450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/9/23
|
8/3/23
|
11/2/23
|
3/12/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
107
|
67.6
|
-
|
267
|
320
|
348
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-38.1
|
-
|
-57.5
|
-91.4
|
-98
|
ROE (net income / shareholders' equity)
|
-
|
-35.5%
|
-53.3%
|
-
|
-34.6%
|
-26.4%
|
-39.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.02
|
-
|
-
|
-
|
2.5
|
2.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
51.71%
|
Announcement Date
|
2/19/21
|
3/3/22
|
3/2/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
20.69
USD Average target price
42
USD Spread / Average Target +103.00% Consensus |
1st Jan change
|
Capi.
|
---|
| +243.12% | 797M | | +9.42% | 114B | | +11.84% | 104B | | -14.15% | 22.41B | | -1.05% | 22.28B | | -5.29% | 19.07B | | -38.29% | 18B | | -4.16% | 17.89B | | +7.99% | 14.28B | | +36.24% | 12.55B |
Bio Therapeutic Drugs
|